A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea.

Choi WS, Quan K, Baber JA, Jaques A, van Rensburg KJ, Li W, Cutler MW, Kalinina EV, Anderson AS, Swanson KA, Gurtman A, Munjal I, Jeongwol C3671053 Clinical Trial Group

Open source

DOI
10.3390/vaccines14090773
Published
2026 Sep 3
Container
Vaccines
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/vaccines14090773,
  title = {A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea.},
  author = {Choi WS and Quan K and Baber JA and Jaques A and van Rensburg KJ and Li W and Cutler MW and Kalinina EV and Anderson AS and Swanson KA and Gurtman A and Munjal I and Jeongwol C3671053 Clinical Trial Group},
  year = {2026},
  journal = {Vaccines},
  doi = {10.3390/vaccines14090773},
  url = {https://doi.org/10.3390/vaccines14090773}
}

RIS

TY  - JOUR
TI  - A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea.
AU  - Choi WS
AU  - Quan K
AU  - Baber JA
AU  - Jaques A
AU  - van Rensburg KJ
AU  - Li W
AU  - Cutler MW
AU  - Kalinina EV
AU  - Anderson AS
AU  - Swanson KA
AU  - Gurtman A
AU  - Munjal I
AU  - Jeongwol C3671053 Clinical Trial Group
PY  - 2026
JO  - Vaccines
DO  - 10.3390/vaccines14090773
UR  - https://doi.org/10.3390/vaccines14090773
ER  - 

APA

WS, C., K, Q., JA, B., A, J., KJ, V. R., W, L., MW, C., EV, K., AS, A., KA, S., A, G., I, M., & Group, J. C. C. T. (2026). A Randomized Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Bivalent RSVpreF Vaccine in Older Adults in Korea.. Vaccines. https://doi.org/10.3390/vaccines14090773

Source records